BioSpace News Archive

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the election of Ms. Susan Hirsch to Agenus’ Board of Directors.

Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, will hold a conference call on Thursday, November 5, 2020 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2020. A press release detailing these results will be issued prior to the call. Calyxt Chief Executive Officer Jim Blome and Chief Financial Officer Bill Koschak will host the conference call, followed by

Motus GI Holdings, Inc.announced that it will host a key opinion leader call on improving inpatient endoscopy outcomes with the Pure-Vu® system on Friday, October 16, 2020.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today preliminary sales and adjusted earnings per share (EPS) results for the third quarter of 2020. Net sales grew 26% at actual rates, and also rose 26% at constant exchange rates (CER), to $481.3 million from $382.7 million in the same period of 2019 – a higher rate than the outlook for the third quarter of 2020 for 16-21% CER sales growth a

In conjunction with OCD Awareness Week, BrainsWay partners with mental health influencers and patients to increase education around misrepresentation of the disorder

The Pancreatic Cancer Action Network (PanCAN) announced today the launch of Precision PromiseSM, the first of its kind adaptive clinical trial platform for pancreatic cancer patients.

Kaiser Permanente, the nation’s largest integrated nonprofit health care system, has created guidance that can be widely adopted across the health care industry for assessing COVID-19

Marchon Eyewear, Inc., one of the world’s largest manufacturers and distributors of quality eyewear and sunwear, announced an industry-first partnership with Eastman, a global specialty materials company.

CytoAgents, a clinical-stage biotechnology company, announced today that enrollment has started for its Phase 1 clinical trial with lead drug candidate, GP1681, for treatment of COVID-19 “cytokine storm,” clinically known as hypercytokinemia.

By Integrating Critical Information at Point of Care, Rhazdrugs Improves Frontline Healthcare Staff Safety, Raises Bar for USP 800 Compliance